Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H4N2O2 |
| Molecular Weight | 113.0794 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N[13C](=O)NC=C1
InChI
InChIKey=ISAKRJDGNUQOIC-AZXPZELESA-N
InChI=1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)/i4+1
Otsuka Pharmaceutical was developing URACIL C-13, 2- ([2-13C]uracil) breath test for diagnosis of cancer and gastric emptying disorders. Dihydropyrimidine dehydrogenase (DPD) deficiency is critical in the predisposition to 5-fluorouracil dose-related toxicity. The phenotypic [2-(13)C]uracil breath test (UraBT) demonstrated 96% specificity and 100% sensitivity for identification of DPD deficiency. Phase II development of the breath test was ongoing. As phase II clinical study didn't exploit performance as diagnostic medicines, the development of [2-13C]uracil was discontinued.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
35803-45-3
Created by
admin on Sat Dec 16 07:39:29 GMT 2023 , Edited by admin on Sat Dec 16 07:39:29 GMT 2023
|
PRIMARY | |||
|
DTXSID70189336
Created by
admin on Sat Dec 16 07:39:29 GMT 2023 , Edited by admin on Sat Dec 16 07:39:29 GMT 2023
|
PRIMARY | |||
|
10171240
Created by
admin on Sat Dec 16 07:39:29 GMT 2023 , Edited by admin on Sat Dec 16 07:39:29 GMT 2023
|
PRIMARY | |||
|
OZF8J4VAIK
Created by
admin on Sat Dec 16 07:39:29 GMT 2023 , Edited by admin on Sat Dec 16 07:39:29 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
